A history of prolonged diphenylhydantoin (Dilantin) therapy was reported by 8 of 516 patients (1.6%) with Hodgkin's disease or non-Hodgkin's lymphoma, as compared with 3 of 516 patients (0.6%) with other cancers, and 2 of 516 (0.4%) tumor-free individuals. The findings, together with other published data, suggest a small excess risk of malignant lymphomas in patients receiving long-term treatment with this drug. The immunosuppressive effects of chronic diphenylhydantoin therapy may be involved in the pathogenesis of these neoplasms.
No takes yet. Share an insight, caveat, or question.
Li et al. (1975) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: